Research Fellow in Economics, Oriel College
Research Fellow and Economist, Spacial Ecology and Epidemiology Group and Malaria Atlas Project, Department of Zoology
Principal Investigator, Oxford Martin Programme on Vaccines, and Project Leader, Vaccine Health Economics
& Beyond: Causes and Consequences of the Global Financial Crisis Andrew Farlow, Oxford University Press
Read about it here
448 pages | 234x156mm
UK RRP: £25
In all good bookstores from April 2013
note that the book is over 400 pages in length (including Preface, bibliography and index) and not, as some
Please note that the book is over 400 pages in length (including Preface, bibliography and
index) and not, as some
entries still say, 256 pages. After it was commissioned, it became a much more substantial book,
website entries still say, 256 pages. After it was commissioned, it became a much more substantial book,
devoting eight of its twelve chapters to
devoting eight of its twelve chapters topolicy responses after the crash.
also note that the title and cover design were released in the spring of 2009 and widely available online from that date, and predate
Please also note that the title and cover design were released in the spring of 2009 and widely available online from that date, and predate
similar-sounding (and, some would say, looking) book on the crash by Gorden Brown.
similar-sounding (and, some would say, looking) book on the crash by Gorden Brown.
Global Health: Pharmaceutical research and development; global health financing and delivery; innovation and technology transfer issues in global
health settings; measurement of socioeconomic impact of health interventions; application of financial and risk management tools to global health
analysis; market, pricing, and launch strategies, especially in resource-poor settings. The approach is highly interdisciplinary and policy-orientated,
mixing science, economics, epidemiology, finance, and management practice
Financial Markets: Banking, equity, currency, and real estate; financial instability; monetary policy; bubbles
| - A review of the evidence for UK policy on chickenpox and shingles vaccines has just been completed and shortly will be submitted. |
- A paper analyzing the burden of disease for dengue in Cambodia and Thailand is awaiting data clearance before it can be published.
- A paper, with colleagues outside of Oxford, on the cost of dengue outbreaks has just been completed.
- Other work in progress:
‘Cost of dengue in Africa'
'Key Issues in the Economics of Pandemic Flu Vaccine’
‘Prize Funds for Drugs and Vaccines: Principles and Challenges’
‘New Estimates of Drug Development Costs'
'Renal failure and kidney transplant surgery in resource-poor settings'
SOME RECENT ACTIVITY:
The global distribution and burden of dengue Samir Bhatt, Peter W. Gething, Oliver J. Brady, Jane P. Messina, Andrew W. Farlow, Catherine L. Moyes, John M. Drake, John S. Brownstein, Anne G. Hoen, Osman Sankoh, Monica F. Myers, Dylan B. George, Thomas Jaenisch, G. R. William Wint, Cameron P. Simmons, Thomas W. Scott, Jeremy J. Farrar & Simon I. Hay, Nature, 07 April 2013. This has already been heavily covered in the global media, such as AP, Reuters, The Hindu, Science
PLOS Medicine, September 2012.
the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus Oliver
J. Brady, Peter W. Gethin, Samir Bhatt, Jane P. MesThe global distribution and burden of dengue, Samir Bhatt, Peter W. Gething, Oliver J. Brady, Jane P. Messina, Andrew W. Farlow, Catherine L. Moyes, John M. Drake, John S. Brownstein, Anne G. Hoen, Osman Sankoh, Monica F. Myers, Dylan B. George, Thomas Jaenisch, G. R. William Wint, Cameron P. Simmons, Thomas W. Scott, Jeremy J. Farrar & Simon I. Hay, Nature, sina,
John S. Brownstein, Anne G. Hoen, Catherine L. Moyes, Andrew W. Farlow, Thomas W. Scott, Simon I. Hay ,
,PLoS Neglected Tropical Diseases, August 2012.
I have recently joined the Malaria
Atlas Project where I am working on dengue, as part of a broader effort to apply some of my economic and financing thinking to tackling diseases. My dengue work is financed by the EU-funded International Research Consortium on Dengue Risk Assessment, Management and Surveillance.
A Review of Malaria Vaccine Candidate RTS,S/AS02A, January 2010. This will as new trial data comes out.
Stop TB Partnership Working Group on New Vaccines: Task Force on Economics and Product Profiles. Meeting wrap up presentation: Gaps and Plans, Veyrier-du-Lac, October 2009. Meeting report. Meeting Executive Summary. The third meeting of the Task Force was in Oxford in the summer of 2010 and involved those in Oxford working on TB vaccines
‘“Where’s all the money gone?” Financial crisis and global health spending: Priority setting past, present and future’, Vice Chancellor’s Global Health Research Forum, University of Oxford. September 2009
“Financial Meltdown and Neglected Diseases: Who will pay the price?” Talk given at launch event of first G-FINDER (Global Funding of Innovation for Neglected Diseases) report, Royal College of Physicians, London, February 2009. See the video of all speakers and panel and audience discussion here. Copy of talk here
TB Vaccine Scoping Study Part 1 (Epidemiology, cost effectiveness and socioeconomic issues; Demand, revenue, adoption, pricing and cost issues) for the Task Force on Economics and Product Profiles, of the Stop TB Working Group on New Vaccines (WHO, Aeras Global TB Vaccine Foundation, and Bill and Melinda Gates Foundation), December 2008. Meeting Report. Meeting Executive Summary
TB Vaccine Scoping Study Part 2 (Lessons for TB from a selection of other vaccines) for the Task Force on Economics and Product Profiles, of the Stop TB Working Group on New Vaccines (WHO, Aeras Global TB Vaccine Foundation, and Bill and Melinda Gates Foundation), December 2008
TB Vaccine Discussion Points for Task Force on Economics and Product Profiles, December 2008
Stop TB Working Group on New Vaccines: Task Force on Economics and Product Profiles: Discussion Point PowerPoint for first meeting, London School of Hygiene and Tropical Medicine, 11-12 December 2008
Magnesium Sulfate for the Management of Eclampsia and Pre-eclampsia: Some Economic and Cost Reflections, PowerPoint presented in 2007, posted December 2008 following request
Childhood immunisation against varicella zoster virus: Editorial, British Medical Journal, August 2008 (or toll free link)
Global Health Research Agenda, prepared following Oxford Conference on Innovation and Technology Transfer for Global Health in September 2007. The conference website, Innovation and Technology Transfer for Global Health, no longer exists and therefore the files have been given a section, below, on this webpage.
The Malaria Product Pipeline: Planning for the Future. Major report by Moran M., Guzman J., Ropars A., Jorgensen M., McDonald A., Potter S., and Haile-Selassie H. The George Institute for International Health and Global Forum for Health Research. With a colleague, Simone Ghislandi (see p. 93), we provided the portfolio simulation framework used in this report for projecting the future funding needs of the global malaria vaccine and drug pipeline, working out the gaps and how to make the pipeline more optimal. September 2007. See a ScienceDaily article about the findings of this report here.
Independent assessment of the case for investment in tuberculosis vaccines. Report prepared for Aeras Global TB Vaccine Foundation and Bill and Melinda Gates Foundation, July 2007.This report (and associated Aeras/Gates meeting in Washington at which I presented the findings) was an independent peer review of key evidence and provision of my own evidence during the negotiations between Aeras and the Bill and Melinda Gates Foundation over a $200m grant, at the time the largest grant by the Foundation to a PDP (Product Development Partnership). I am told that this report was important in identifying potential commercial partners for the new MVA85A TB vaccine candidate developed at the University of Oxford (see a press release here).
A Global Medical Research and Development Treaty: An answer to global health needs? International
Policy Network Working Papers on Intellectual Property, Innovation and Health, June 2007
I am working on a chapter ‘The role of indicators in the global financial crisis’, for a book project ‘A world of Indicators: the production of knowledge and justice in an interconnected world’ for Cambridge University Press.
A early opinion piece on the global financial crisis can be found here
Part Three: UK House Prices, Consumption and GDP in a Global Context January 2005. Recommended by Hamish McRae in the Independent on Sunday I am told by investment banking colleagues that this was very prescient and ‘got right many key points’ about the subsequent financial crash. Part Three explores a range of issues key to the global financial crisis of a few years later, including: the unsustainable imbalances in global financial flows, savings, consumption and government spending, particularly with respect to the US and China but also the UK; the overly-loose monetary policy; the disregard for risk that showed up in speculative investment in mortgage and housing markets in a ragne of countries and the overuse of debt-based finance on a global scale; the dangers when the financial bubble of the late 1990s shifted from being equity-based to become debt-based in the 2000s, and the way in which it would shift then to government balance sheets (a ‘shifting bubble’); the precarious short-term revolving nature of much mortgage activity and the potential for financial and real economic contagion to spread to the rest of the world from problems in banking related to the property market, and the way in which this would put the US and its mortgage banking market, but also that of countries like the UK, at the centre of a global downswing; the balance-sheet nature of the ensuing economic problems as households sought to deleverage and increase their savings at the same time as governments were much more fiscally burdened too; the need in advance to hold smaller budget deficits in developed economies to help cushion this impact when it came; the particular dangers for the UK because of a growing government deficit and shrinking cushion, that made the UK particularly vulnerable when correction eventually came; the unconventional monetary policy that would be needed when standard interest rate tools could not go below zero percent; and the knife-edge balance between inflation and deflation during the recovery phase.
and Buyers January 2004 version (updating of May 2003 version, prepared for Credit
Suisse First Boston).
Recommended by Martin
Wolf in the Financial Times
Out of the blue, in April 2010 I was told that the article by Martin Wolf in the Financial Times that outlined the key arguments of Part One and Part Two of my analysis running up to the recent financial crisis caused British Prime Minister Tony Blair sufficient concern that he asked the UK Treasury for a full briefing note. This got some coverage here: A Prime minister who knows something about the economy? (“In fact, according to some documents teased out of the Treasury ... it turns out Blair was rather more worried about the state of the economy than you might have thought…It underlines the simple fact that the Treasury under Gordon Brown was blind to the possibility that things could go horribly wrong – even within the confines of Downing Street. It turns out no-one was allowed to challenge the ‘end to boom and bust’ trope – even Tony Blair himself”); here (which contains the Freedom Of Information request, that I knew nothing about, that led to this revelation, and also a link to the Treasury briefing); and here (the Treasury briefing, in its comments regarding first time buyers, is described as an “admission from the Treasury under Gordon Brown's reign as chancellor [that] runs counter to previous government rhetoric...etc.”). It is always reassuring to hear that people in high places get to hear about your work, less encouraging to hear that it didn’t make any difference!
Four: Risk premia in housing markets
Slightly shortened versions of the following papers appeared for Oxford Analytica:
Bubbles and Emerging Market Crises November 2003
Selected recent presentations, guest lectures, and meetings
2013: Accra, Ghana, meeting on dengue in Africa. I am also meeting colleagues in Ghana working on efforts to scale up renal transplant surgery in Africa.
:Max-Planck-Institut für ethnologische Forschung, Halle, Germany, three-day workshop,‘Relocating Science and Technology. Global Knowledge, Traveling Technologies and Postcolonialism. Perspectives on Science and Technology Studies in the Global South’, participant.
July 2012: Büro für Technikfolgeabschätzung beim Deutsschen Budestag (TAB), Berlin. Meeting with TAB regarding a project of German and other academics (on which I am an external advisor) to advise the German Bundestag (parliament) on ‘innovative and alternative concepts for drug development to improve health in African countries’
2011: Stockholm, European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE), 6-8 November. Invited plenary speech: Enhancing
health and health equity through vaccination programmes, session on 'Economics and Societal Value of Vaccines'; I returned to the theme of the need for a higher-efficacy malaria vaccine goal and discussed progress on dengue vaccines. Conference sponsored by European Centre for Disease Control and Prevention (ECDC) and jointly organized by ECDC, EPIET (European Programme for Intervention Epidemiology), EAN (EPIET Alumni Network), TEPHINET EUROPE (Training Programs in Epidemiology and Public Health Interventions Network). (some slides had copyright images removed before going online).
October 2011: Freiberg IDAMS meeting.
June 2011: Wissenschaftscolleg zu Berlin, Colloquium (10 minute introduction, 50 minute presentation, one hour of questions) 'The Financial Crash: Causes, Responses, Consequences'.
ethnologische Forschung, Halle, Germany, conference: 'A World of Indicators: Knowledge Technologies of Regulation, Domination, Experimentation and Critique in an Interconnected World'. Presentation 'Science, Innovation and Global Health Policy: The Evolving Role of Indicators'.
May 2011: 5-day meeting at Wissenschaftscolleg zu Berlin, 'Caring for African Health Care: Reading Clinical Case Studies for Systemic Insights'. Meeting report Caring for African Health Care: Reading Clinical Case Studies for Systemic Insights (pp308-317) by Steven Feierman and Julie Livingston.
zu Berlin Focus groups: Limits
to Disease Control - Failures in Disease (convened by Janis
Antonovics of the Univeristy of Virgina) and Professional
Dilemmas of Medical Practice in Africa (convened by Steven
Feierman of the University of Pennsylvania and Julie
Livingston of Rutgers University). The first focus group was a tremendous help in developing my thinking on which vaccines are more and less likely to suffer long-term declines in population-level efficacy on account of evolution, and how packages of interventions might better work given the workings of evolution. The second group encouraged me even more to develop policy that better serves the needs of those delivering medical care in resource-poor settings, and introduced me to some astonishing people who somehow mix academic thinking with medical practice and daily life in very resource-poor settings.
2010, Oriel College Oxford. Stop
TB Partnership Working
Group on New Vaccines: Task Force on Economics and Product Profiles, Presentation: Financing for TB Vaccines in a Financially-Constrained World.
2010 (31 May-3 June) Panama City, Panama. TDR (UNICEF/UNDP/World Bank/WHO) Disease Reference Group (DRG) on Dengue and other Emerging Viral Diseases of Public Health Importance. Stream 4: health policy research contributing to adequate public health response. Presentation: Factors Leading to Success or Failure of National Programmes and Global Funding in Dengue.
2007-2010: My approach to global health issues is highly collaborative. One objective has been to share knowledge and learning across different groups working on similar themes; good practice can therefore be picked up, shared and encouraged, and less good approaches can be avoided and replaced. Just recently, this has been extremely valuable in my thinking about TB and malaria vaccines, drugs and diagnostics in particular. The research group held in-depth meetings with the Malaria Vaccine Initiative (MVI); International AIDS Vaccine Initiative (IAVI); Aeras Global TB Vaccine Foundation; Foundation for Innovative New Diagnostics (FIND); International Partnership for Microbicides (IPM); TB Alliance; PATH (Human papillomavirus, meningitis, and Japanese encephalitis vaccine teams); Drugs for Neglected Diseases Initiative (DNDi); Novartis Institute for Tropical Diseases; Sanofi Pasteur; GlaxoSmithKline; InViragen; Hawaii Biotech; Merck Vaccines; Pfizer; WHO (Immunization Vaccines and Biologicals, and Initiative for Vaccine Research); GAVI Alliance; UNICEF; Oxford Insect Technologies (OXITEC); Swiss Tropical and Public Health Institute; Lille University; Imperial College London; Spatial Ecology and Epidemiology Group, Zoology Department, Oxford; Atmospheric, Oceanic and Planetary Physics, Oxford; the Institute for Emergent Infections of Humans, Oxford Martin School; and other Oxford infectious disease mapping researchers.
December 2010: UK Department of Health, International Division, Stakeholder meeting ahead of WHO Executive Board meeting in January 2010.
Encouraged by senior colleagues in the Bill and Melinda Gates Foundation, NIH, WHO, industry, and academia (though not the business school where I was based), I encouraged the Bill and Melinda Gates Foundation to finally deal with PDVI, a failing PDP based inside the IVI in Korea, that had, in the words of leading Foundation figures, wasted large chunks of the money the Foundation had given it, mismanaged and bullied many grantees, slowed the advance of a portfolio of potential dengue vaccines, held back vital economic/impact work for at least five years, and failed to sufficiently advance an access agenda for dengue vaccines. For the first time, the Foundation held a competition to replace a PDP, removed managers, and set up a new collaboration, the DVI (that included parts of PDVI).
October 2009: Fondation Merieux, Veyrier-du-Lac, France. Second meeting of the Task Force on Economics and Product Profiles for new TB vaccines (WHO, Aeras Global TB Vaccine Foundation, and Bill and Melinda Gates Foundation)
September 2009: Vice Chancellor’s Global Health Research Forum, University of Oxford: Presentation: ‘“Where’s all the money gone?” Financial crisis and global health spending: Priority setting past, present and future’
March 2009: Joint Committee on Vaccination and Immunisation (JCVI), varicella zoster subgroup meeting, Department of Health, London
February 2009: International Consulting Economists' Association, The Institute of Commonwealth Studies, London. Presentation: ‘The Global Financial Crisis: Causes and Cures’
February 2009: G-FINDER (Global Funding of Innovation for Neglected Diseases), George Institute for international Health (project financed by Bill and Melinda Gates Foundation) report launch meeting, Royal College of Physicians, London. Short talk and panel member
December 2008: London School of Hygiene and Tropical Medicine. First meeting of the Task Force on Economics and Product Profiles for new TB vaccines, presentation (WHO, Aeras Global TB Vaccine Foundation, and Bill and Melinda Gates Foundation)
Impact Fund meeting, Lincoln
College, Oxford. Response presentation and panel discussion
November 2008: Zoology Dept, University of Oxford, ‘Science and Public Health Policy’ presentation and discussion
October 2008: Pfizer Inc Headquarters, New York, ‘Global Health Access: The Challenges of Finance and Sustainability’
2007: Organized a follow-up two-day meeting in Oxford pulling together two-dozen dengue modellers, in particular several groups in Oxford, economists, and researchers working on dengue burden of disease.
2007: I organized and lead a day-long workshop pulling together three teams of dengue transmission modelers and several groups working on dengue economics (about 25 individuals from Switzerland, Lille, US, UK (London and Oxford)), to explore methological strengths and weaknesses, set up guidelines and standards for work on the economics of dengue vaccines, and to improve the consistency of dengue economics evidence to be used to guide vaccine introduction. The work was subsequently taken over by PDVI and then eventually DVI.
2007: MacArthur Foundation workshop on maternal mortality, University of Oxford. Social Science convenor. Presentation: ‘Magnesium Sulfate for the Management of Pre-Eclampsia and Eclampsia: Some Economic and Cost Reflections’
May 2007: WHO Geneva missions (China, South Korea, Germany, Brazil). Discussions.
November 2006: Tanaka Business School, Imperial College, London, ‘Brainstorming meeting on universal access to HIV medicines’ (Imperial College London, Department for International Development [DfID], International HIV/AIDS Alliance, and Stop AIDS Campaign). Participant.
2006-December 2008: Senior Research Fellow, Saïd Business School, Oxford. During this period I pulled together a research group of about ten people (seven full-ime and three part-time), was awarded $1.4 million in grant money, and led a $50 million bid for work on global health (which in the end nobody was granted). From 2009 my institutional focus shifted back to working with those engaging in Oxford's long-established and flourishing global health programs.
June 2006: Brussels. 'Connecting the Chain: A concerted "end to end" approach to the development of drugs and vaccines against poverty-related diseases'. High-level, invitational stakeholder forum (Netherlands Ministry of Foreign Affairs, European and Developing Countries Clinical Trials Partnership [EDCTP] and Netherlands-African Partnership for Capacity Development and Clinical Trials [NACCAP]). Invited participant
2006: I helped to build a small (three-person) research group working on how to use modern marketing techniques to reach the 'undelivered' with vaccines, and to push vaccine coverage above 90% (I argued it would help PDVI lead the field on an issue that was neglected but becoming increasingly important). This was several years ahead of its times. Four years later the Bill and Melinda Gates Foundation announced a goal of scaling up the delivery of life-savings vaccines in developing countries to 90% coverage, and six years later the World Health Assembly of the WHO endorsed a plan to increase coverage amongst other moves. The Oxford team dispersed and moved on.
May 2006: Advised TB Alliance on TB Drug Development Portfolio Figures. Analysis of Monte Carlo simulations of TB drug portfolio
2005: Geneva, Switzerland, WHO Commission on Intellectual Property Rights, Innovation and Public Health, stakeholder meeting. Participant
2003: Oriel College, Oxford, Senior Library. During the celebrations to launch the Mandela Rhodes Foundation, organised a public lecture on ‘Democracy in South Africa’ for Patricia de Lille, leader of the Independent Democrats, a South African political party, who along with Nelson Mandela and others had helped to write the new Constitution of South Africa. The lecture, and discussion, was attended by about 100 Rhodes Scholars of all ages, including two US Senators. Organised meetings with a range of UK government Ministers and officials and with UK groups working on HIV.
Other academic service, refereeing, advice, etc.
I try to be as generous as I possibly can be regarding the work of a very wide range of global health colleagues as we collectively explore how to improve and advance global health policy.
I have recently become adviser to a project to advise the German Parliament on 'innovative and alternative concepts for drug development to improve health in African countries'
I am (just recently) working with a number of colleagues (UK, Africa, WHO) on a project on renal failure and transplantation in very resource-poor settings in Africa. The work is at a very early stage, but is emblematic of the extreme challenges, yet possibilities, of health care under extreme resource constraints.
Oxford Conference on Innovation and Technology Transfer for Global Health (with the generous financial support of the Bill and Melinda Gates Foundation), and jointly in charge of conference dissemination strategy.
WHO Expert Working Group on R&D Financing: Expert testimony on evaluation framework, evaluation criteria and Inventory of financing proposals of the EWG. Over the years I have promoted the notion of policy makers looking at these issues through the lenses of ‘risk’ and ‘coordination’ and this is reflected here. My testimony is here.
Pharmaceutical R&D Policy Project, LSE (which moved to the George Institute for International Health) and the Health Policy Division of the George Institute for International Health, Australia; Help with developing modelling tools (especially portfolio analysis of malaria drugs and vaccines and thoughts on the G-Finder process, both financially supported by the Bill and Melinda Gates Foundation) and pre-publication review.
Global Development Advisors: Advice on research into funding mechanisms and R&D incentives for malaria (funded by the Bill and Melinda Gates Foundation). Independently reviewed the IFF-Nd (International Financing Facility for Neglected Disease) proposal when it was going through HM Treasury in 2007. Academic contributor to work on extensions of the principle of the ‘Affordable Medicines Facility for malaria’ (the financing mechanism to subsidize malaria ACTs globally implemented by the Global Fund with strong support from the Bill and Melinda Gates Foundation) to other development topics inside and outside of global health. Advice on Fund for R&D in Neglected Diseases (FRIND).
Results for Development Institute: Early help thinking through how to set up rigorous and independent analysis for a three-year project funded by the Bill and Melinda Gates Foundation titled ‘Assessing Innovations in Global Health R&D Policy and Financing’. Project Page here. I hope to be able to make useful further contributions as the project progresses.
Office of Health Economics, London: Feedback on a selection of work, including independent peer review of R&D modelling by OHE for Bill and Melinda Gates Foundation.
X PRIZE Foundation: Advice on the design of a prize
for effective diagnosis of tuberculosis in the developing world. Planning grant to develop the prize provided by the Bill and Melinda Gates Foundation.
World Economic Forum, i.e. ‘Davos’, Global
Health Initiative, ''Tackling
Tuberculosis: The Business Response' 2008, reviewed report for authors.
I am currently heavily engaged in the Bill and Melinda Gates Foundation’s efforts to improve the management and efficiency of the dengue vaccine space. Watch this space as they say!
At the moment I am working in particular with a wide range of colleagues in WHO, industry and academia on the idea of creating more rigorous and independent cost effectiveness analysis, and encouraging more decision-making capacity in countries themselves to use that analysis so that they have more influence over the funding decisions at the global level. Part of this effort involves thinking about better measurement of both inputs and health outcomes.
Routledge: Economic book referee
Oxford University Press: Economic book referee
Joint Committee on Vaccination and Immunisation (JCVI): Peer review analysis of cost effectiveness evidence submitted to JCVI
The Lancet: Academic referee
Medicine: Academic referee
Neglected Tropical Diseases: Academic Referee
Health Policy and Planning (LSHTM): Academic Referee
National Institute for Health Research: Research grant peer reviewer
Research: Academic peer-reviewer
Council: Grant peer reviewer
for Global Development: insights, contributions and comments on front-loading
finance into vaccines and other global health work.
Teaching at Oxford
These days I do only a very small amount of undergraduate teaching, and mostly concentrate on research.
Since 2007 I have lectured ‘Vaccine Deployment and Policies’ for the Vaccinology Module of the Masters of Science (MSc) in Global Health. For the past five years my lecture slides/notes have only been available on Oxford's internal weblearn system. In the face of numerous requests, and as an experiment, I am finally putting the slides online (January 2013), in the hope that others will find some value in them. The materiel is sourced from all over the place; if anyone finds material that they own and object to it being used in this way, please email me and I will amend, credit the source more comprehensively, or remove. My intention is not to offend or to take advantage, but to make a resource, that several generations of students have told me that have found very valuable, available to other students wherever they may be in the world.
Slides for this are gathered in the following batches:
I have advised Oxford students and researchers on a wide range of global health research projects. Recent projects have included:
i) The R&D issues surrounding pediatric antiretrovirals for children with HIV;
ii) Vaccine strategies (in particular choice of vaccine) for global polio eradication;
iii) A comparative study of health system performance in several developing countries;
iv) The financial aspects of developing a telediagnostic kit and service for malaria and chikungunya infections in rural areas of Kenya;
vi) Global health IP issues;
vii) Product Development Partnerships, governance and incentive issues;
viii) Pneumococcal vaccines;
ix) The economics of thermostable vaccines;
x) Innovative’ global health financing.
As best I can, I also give feedback to students from outside Oxford who inquire about their global health research projects.
In 2004-2006, I was an Exam Moderator for the Prelims Economics component of the degrees of Philosophy, Politics & Economics, and History & Economics, at the Department of Economics, University of Oxford. Occasionally I am an M.Phil./M.Sc. thesis examiner in areas of my expertise.
I was in charge of Economics studies at Oriel College for six years till 2006, teaching both macroeconomics and microeconomics at all levels, before concentrating on my global health research. I previously taught (microeconomics, macroeconomics, industrial organisation, banking, and finance) at several other colleges of the University of Oxford: I was Tutor for Economics at Christ Church College, St. Edmund Hall, Hertford College, Worcester College, and Keble College.
I was part-time research officer for a year at Oxford's (then) Institute of Economics and Statistics.
If quoting a position being taken by Andrew Farlow, please refer to the original works above (this section is not up-to-date)
Zeneca, Italia, 22 January 2007 (web)
In September 2007 I helped to organise an 'inaugural' conference on innovation, technology transfer and global health, which bought together 100 hand-picked, highly diverse, key thinkers and practitioners in global health. Together with Gill Samuels, Foundation Chair of the Global Forum for Health Research, based in Geneva, I was in charge of gathering the lessons and disseminating the findings. Most of the work for write-up was done by Rachelle Harris and Sarah Miller. The Bill and Melinda Gates Foundation generously provided funds for thirty delegates from developing and middle-income countries so that the discussion was firmly rooted in their experiences. With the kind permission of his widow, we called these supported delegates ‘Sanjaya Lall Fellows’ in memory of Oxford economist Sanjaya Lall. The Bill and Melinda Gates Foundation also generously provided funds to cover the conference write-up, website, long-term dissemination of findings, and the development of a future research agenda. The delegates met for four days in the Business School, and were housed in Oriel College.
With the support of the Bill and Melinda Gates Foundation, a purpose-built webpage was set up, subsumed under the business school website,. After this was switched off, at the end of a year, the files were transferred here for safe-keeping. If funding and logistics ever permit, a follow-on conference will be arranged and the website will be re-instated.
IN MEMORY OF SANJAYA LALL:
MAIN CONFERENCE FILES:
REPORTS ON INDIVIDUAL SESSIONS:
Plenary Lecture by Dr Carlos Morel of the Oswaldo Cruz Foundation (FIOCRUZ), Brazil
Session 1: Dimensions of the Challenge
Session 2: Strategies for Securing Product Availability and Access
Session 3: The Interface of Science, Technology Transfer and Access
Session 4: Partnerships in Promoting Innovation and Managing Risk (I)
Session 5: Partnerships in Promoting Innovation and Managing Risk (II)
Session 6: Managing Intellectual Property for Health and Agricultural Innovation
Session 7: Financing for Innovation and Technology Transfer
THE CONFERENCE PLENARY LECTURE:
Morel, Oswaldo Cruz Foundation (FIOCRUZ), Brazil
A SELECTION OF INDIVIDUAL PRESENTATIONS:
Some of the presentations below are not password-protected. Several presentations were password-protected and are no longer available.
Abboud, IAVI, USA
Farlow, University of Oxford, UK
Flores, Flores & Associados, Universidad de Concepcion, Chile
Free, PATH, USA
Ganguli, Vision-IPR, India
Geraghty, Genzyme Corporation, USA
Jaffe, University of Oxford, UK
Lippoldt, OECD, France
Madkour, Library of Alexandria, Egypt
Makinde, NEPAD, Senegal
Mallett, Pfizer Inc., USA
Maskus, University of Colorado, USA
Moran, The George Institute, Australia
Morris, African Centre for GeneTechnologies, South Africa
Purohit, Ranbaxy Laboratories Ltd, India
Rangel-Aldao, Simon Bolivar University, Venezuela
Reeler, Axios International, France
Satyanarayana, Indian Council of Medical Research, India
Sundari, The Center for Health System and Policy Research and Development, MOH, Rep. Indonesia
Towse, Office of Health Economics, UK